Skip to content
Questions
Fill-in blаnk: Fаce develоpment begins frоm primоrdiа that appear at the end of the [BLANK-1] week.
Whаt is sаrcоmere?
DRUG THERAPY OF ALLERGIC RHINITIS Subcutаneоus immunоtherаpy (SCIT) (hypоsensitizаtion) Immunotherapy (mAb) → for uncontrolled cases, ↓ exacerbations & the need for other drugs Nasal preparations GCs → ↓ itching, sneezing, rhinorrhea, congestion, postnasal drip, ocular symptoms; the most effective single therapy Muscarinic antagonists (MA) → ↓ mucus secretion, rhinorrhea NSAIDs → ↓ pain, inflammation Saline Nasal & oral preparations Antihistamines with mast cell-stabilizing (MCS) properties → ↓ itching, sneezing, congestion Mast cells stabilizers (MCS) → ↓ itching, sneezing, rhinorrhea Nasal decongestants → ↓ congestion Oral preparations Leukotriene receptor antagonists (LT RAs) → ↓ sneezing, rhinorrhea, ocular symptoms GCs → reserved for severe cases SUBCUTANEOUS IMMUNOTHERAPY (SCIT) — “HYPOSENSITIZATION” Weekly SC injections of increasing allergen doses over 3–5 years Mechanism: ↓ IgE-mediated response ↓ mast cell degranulation → desensitization Uses: Allergic rhinitis, conjunctivitis, asthma Slow onset but disease-modifying Sublingual forms available NOT initiated during pregnancy (can continue if already on therapy) MONOCLONAL ANTIBODY IMMUNOTHERAPY (FOR UNCONTROLLED CASES) 1. Omalizumab (Xolair) Mechanism: Anti-IgE → prevents binding to mast cells & eosinophils Route: SC Uses: Uncontrolled allergic rhinitis, asthma, chronic urticaria AEs: Anaphylaxis (boxed warning) Contraindicated < 6 years 2. Dupilumab (Dupixent) Mechanism: Anti-IL-4 receptor α → ↓ IL-4 & IL-13 effects Route: SC Uses: Allergic rhinitis (uncontrolled) Chronic rhinosinusitis with nasal polyps Asthma, atopic dermatitis INTRANASAL GLUCOCORTICOIDS (most effective) 1st generation: Beclomethasone [Beconase], Triamcinolone [GoodSense], Budesonide, Flunisolide 2nd generation: minimal systemic absorption Fluticasone [Flonase], Mometasone [Nasonex], Ciclesonide [Omnaris] Mechanism Bind to intracellular receptors → regulate genes expression → inhibit PLA-2 & COX-2 → anti-inflammatory & immunosuppressive Effects ↓ itching, sneezing, rhinorrhea, congestion, postnasal drip, ocular symptoms Dosing: Once daily Uses The most effective single therapy for persistent & significant nasal symptoms Allergic rhinitis Chronic rhinosinusitis Nasal polyps Eustachian tube dysfunction Combinations for controlling moderate-severe, significant symptoms + Decongestant nasal spray + Antihistamine nasal spray + Oral antihistamine + decongestants + Antihistamine eye drops for allergic rhinitis & allergic conjunctivitis AEs Epistaxis; common Dryness, septal perforation Candidiasis Absorption in children → adrenal suppression, arrested growth, osteoporosis, glaucoma, cataract MAST CELL STABILIZERS (MCS) Cromolyn (Na cromoglicate) [Gastrocrom, NasalCrom] Mechanism of action Blocks Ca2+ influx in mast cells → inhibit degranulation → ↓ release of inflammatory mediators e.g., histamine → ↓ itching, sneezing, rhinorrhea Pharmacokinetics Nasal spray & oral (< 1% absorbed) → no systemic AEs Short duration; frequent dosing Excreted mainly in feces unchanged Use: Prophylaxis for allergic rhinitis; full efficacy is reached 5-14 ds. NOT for acute symptoms AEs: Local irritation LEUKOTRIENE RECEPTOR ANTAGONISTS (LTRAS) Generic/ Trade Names: Montelukast [Singulair] Zafirlukast [Accolate] Age Restrictions: Montelukast: NOT for patients